Literature DB >> 12702580

The role of hMLH3 in familial colorectal cancer.

Hong-Xu Liu1, Xiao-Lei Zhou, Tao Liu, Barbro Werelius, Gudrun Lindmark, Niklas Dahl, Annika Lindblom.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is commonly associated with at least three currently known DNA mismatch repair genes: (a) hMSH2; (b) hMLH1; and (c) hMSH6. A majority of HNPCC families has identifiable mutations in hMLH1 and hMSH2. When these mutations cause an inherited risk of colorectal cancer, they are also most often associated with microsatellite instability in the tumors. Recently, hMLH3 was suggested to be causative in HNPCC. We screened 70 index patients suggestive of a genetic predisposition for germ-line mutations in hMLH3 with denaturing high-performance liquid chromatography. One frameshift mutation and 11 missense mutations were identified in 16 index patients (23%). Most families presented evidence against hMLH3 as a high risk factor in familial colorectal cancer, and most of the mutations were found in the low risk patients, suggesting hMLH3 to be a low risk gene for colorectal cancer. We demonstrate in one family that a hMLH3 mutation segregated with disease together with a missense mutation in hMSH2, which makes us hypothesize that these mutations work together in an additive manner and result in an elevated risk of colorectal tumors in the family. None of the tumors with hMLH3 mutations showed microsatellite instability, which demonstrates that hMLH3 does not make its contribution to carcinogenesis through an impaired DNA mismatch repair function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702580

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

Review 2.  Lynch syndrome genes.

Authors:  Päivi Peltomäki
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  A loss-of-function variant in DNA mismatch repair gene MLH3 underlies severe oligozoospermia.

Authors:  Shoaib Nawaz; Muhammad Imran Ullah; Beenish Samreen Hamid; Jalwa Nargis; Mehboob Nawaz; Shabir Hussain; Wasim Ahmad
Journal:  J Hum Genet       Date:  2021-01-30       Impact factor: 3.172

4.  Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.

Authors:  Monika Morak; Sarah Käsbauer; Martina Kerscher; Andreas Laner; Anke M Nissen; Anna Benet-Pagès; Hans K Schackert; Gisela Keller; Trisari Massdorf; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

5.  Mutation screening of mismatch repair gene Mlh3 in familial esophageal cancer.

Authors:  Hong-Xu Liu; Yu Li; Xue-Dong Jiang; Hong-Nian Yin; Lin Zhang; Yu Wang; Jun Yang
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

6.  Functional analysis of human mismatch repair gene mutations identifies weak alleles and polymorphisms capable of polygenic interactions.

Authors:  Sandra L Martinez; Richard D Kolodner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

7.  Genomic instability and carcinogenesis: an update.

Authors:  Wael M Abdel-Rahman
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

8.  Some aspects of molecular diagnostics in Lynch syndrome.

Authors:  Grzegorz Kurzawski
Journal:  Hered Cancer Clin Pract       Date:  2006-12-15       Impact factor: 2.857

Review 9.  Impact of DNA mismatch repair system alterations on human fertility and related treatments.

Authors:  Min-hao Hu; Shu-yuan Liu; Ning Wang; Yan Wu; Fan Jin
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

10.  A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer.

Authors:  Fred H Menko; Gertjan L Kaspers; Gerrit A Meijer; Kathleen Claes; Johanna M van Hagen; Johan J P Gille
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.